Check out this article which discusses some strategies to better communicate with regulatory agencies in the preclinical stage of drug approval.
Some of the major themes highlighted are to stay consistent and accurate when discussing your product, think twice about having a meeting with the FDA unless you are fully prepared, engage with medical/scientific communities so you understand the current standard of care and current thinking, and stay up-to-date with patient-advocacy groups.
Our staff is on the phone, email, and face-to-face with FDA on a weekly basis. Let us help you with your FDA interface and submissions. Contact us here.